Unknown

Dataset Information

0

Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma.


ABSTRACT: Metastatic renal cell carcinoma with sarcomatoid histology (SmRCC) is associated with poor survival. No data is available from randomized trials on the efficacy of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors in SmRCC. We identified SmRCC patients from a single institutional database. To identify predictive and prognostic biomarkers, immunohistochemistry (IHC) analysis was performed on the tumor samples for downstream targets of VEGF and mTOR pathways. Survival outcomes were stratified by IHC analysis, extent of sarcomatoid component, Memorial Sloan-Kettering Cancer Center (MSKCC), and Heng risk criteria. Twenty-seven patients with SmRCC were included. First line therapy included targeted therapy (n = 19), immunotherapy (n = 4), cytotoxic chemotherapy (n = 1), and no treatment (n = 3). Median OS was 8.2 months (95% CI 3.8-14.2 months). Median survival in months, based on MSKCC and Heng risk groups, was favorable 89.3 versus 84.5, intermediate 9.5 versus 12.7, and poor 3.9 versus 5.1. None of the IHC markers predicted outcomes of treatment with VEGF or mTOR inhibitors. Only tumor IMP3 expression was associated with inferior OS, although not statistically significant (IMP3 negative 14.2 versus IMP3 positive 4.9 months; HR 0.46, 95% CI 0.16-1.21; P = 0.12). The study was limited by small sample size.

SUBMITTER: Tantravahi SK 

PROVIDER: S-EPMC4320862 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma.

Tantravahi Srinivas K SK   Albertson Daniel D   Agarwal Archana M AM   Ravulapati Sowmya S   Poole Austin A   Patel Shiven B SB   Hawatmeh Jamil S JS   Straubhar Alli M AM   Liu Ting T   Stenehjem David D DD   Agarwal Neeraj N  

Journal of oncology 20150120


Metastatic renal cell carcinoma with sarcomatoid histology (SmRCC) is associated with poor survival. No data is available from randomized trials on the efficacy of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors in SmRCC. We identified SmRCC patients from a single institutional database. To identify predictive and prognostic biomarkers, immunohistochemistry (IHC) analysis was performed on the tumor samples for downstream targets of VEGF and mTOR path  ...[more]

Similar Datasets

| S-EPMC5738119 | biostudies-literature
| S-EPMC4566854 | biostudies-literature
| S-EPMC6752712 | biostudies-literature
| S-EPMC9930281 | biostudies-literature
| S-EPMC4608366 | biostudies-literature
| S-EPMC4412497 | biostudies-literature
| S-EPMC8480366 | biostudies-literature
| S-EPMC6922069 | biostudies-literature
| S-EPMC5725002 | biostudies-literature
| S-EPMC4674298 | biostudies-literature